| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the issuance of a new patent for the company's SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic.
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,036,278 titled, "Smallpox Vaccine for Cancer Treatment," directed to Calidi's SuperNova platform composed of adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus.
Posted In: CLDI
